Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Saved in:
| Title: | Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study |
|---|---|
| Authors: | Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs |
| Source: | Nat Commun Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024) |
| Publisher Information: | Springer Science and Business Media LLC, 2024. |
| Publication Year: | 2024 |
| Subject Terms: | Science, Author Correction |
| Document Type: | Article Other literature type |
| Language: | English |
| ISSN: | 2041-1723 |
| DOI: | 10.1038/s41467-024-48359-1 |
| Access URL: | https://doaj.org/article/c4e454b0c3264101a45975daf5ec89e4 |
| Rights: | CC BY |
| Accession Number: | edsair.doi.dedup.....b3f9daae8fef4546ff625021e3c81f40 |
| Database: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | ISSN: | 20411723 |
|---|---|
| DOI: | 10.1038/s41467-024-48359-1 |